Publicaciones (43) Publicaciones de MATTHIAS DROSTEN

2023

  1. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

    The Journal of clinical investigation, Vol. 133, Núm. 7

  2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. KRAS inhibitors: going noncovalent

    Molecular Oncology

  2. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

    Molecular Oncology, Vol. 16, Núm. 17, pp. 3066-3081

  3. Targeting KRAS mutant lung cancer: light at the end of the tunnel

    Molecular Oncology, Vol. 16, Núm. 5, pp. 1057-1071

2021

  1. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 30

  2. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

  3. RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions

    Methods in Molecular Biology (Humana Press Inc.), pp. 335-346

2020

  1. Requirement for epithelial p38α in KRAS-driven lung tumor progression

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 5, pp. 2588-2596

  2. Targeting the MAPK Pathway in KRAS-Driven Tumors

    Cancer Cell, Vol. 37, Núm. 4, pp. 543-550

  3. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

    Cancer Cell, Vol. 35, Núm. 4, pp. 573-587.e6

2018

  1. Allele-specific mechanisms of activation of mek1 mutants determine their properties

    Cancer Discovery, Vol. 8, Núm. 5, pp. 648-661

  2. ERF deletion rescues RAS deficiency in mouse embryonic stem cells

    Genes and Development, Vol. 32, Núm. 7-8, pp. 568-576

  3. Genetically engineered mouse models of K-Ras-driven lung and pancreatic tumors: Validation of therapeutic targets

    Cold Spring Harbor Perspectives in Medicine, Vol. 8, Núm. 5

  4. The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer

    Cell Cycle, Vol. 17, Núm. 6, pp. 702-711

  5. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling

    Cancer Cell, Vol. 33, Núm. 2, pp. 217-228.e4

2017

  1. A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer

    PLoS Genetics, Vol. 13, Núm. 3

  2. Clasp2 ensures mitotic fidelity and prevents differentiation of epidermal keratinocytes

    Journal of Cell Science, Vol. 130, Núm. 4, pp. 683-688

  3. Genetic validation of cell proliferation via Ras-independent activation of the Raf/Mek/Erk pathway

    Methods in Molecular Biology (Humana Press Inc.), pp. 269-276